Global Neoantigen Vaccine Market Growth (Status and Outlook) 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
LPI (LP Information)' newest research report, the “Neoantigen Vaccine Industry Forecast” looks at past sales and reviews total world Neoantigen Vaccine sales in 2022, providing a comprehensive analysis by region and market sector of projected Neoantigen Vaccine sales for 2023 through 2029. With Neoantigen Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neoantigen Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Neoantigen Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neoantigen Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Neoantigen Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neoantigen Vaccine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neoantigen Vaccine.
The global Neoantigen Vaccine market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Neoantigen Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Neoantigen Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Neoantigen Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Neoantigen Vaccine players cover Pfizer, Merck & Co Inc, Eli Lilly and Company, BioNTech, Roche Holding AG, OSE Immunotherapeutics, Gritstone Bio, Moderna and Avidea Technologies, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Neoantigen Vaccine market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
LPI (LP Information)' newest research report, the “Neoantigen Vaccine Industry Forecast” looks at past sales and reviews total world Neoantigen Vaccine sales in 2022, providing a comprehensive analysis by region and market sector of projected Neoantigen Vaccine sales for 2023 through 2029. With Neoantigen Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neoantigen Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Neoantigen Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neoantigen Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Neoantigen Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neoantigen Vaccine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neoantigen Vaccine.
The global Neoantigen Vaccine market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Neoantigen Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Neoantigen Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Neoantigen Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Neoantigen Vaccine players cover Pfizer, Merck & Co Inc, Eli Lilly and Company, BioNTech, Roche Holding AG, OSE Immunotherapeutics, Gritstone Bio, Moderna and Avidea Technologies, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Neoantigen Vaccine market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
- Personalized Vaccine
- Off-the shelf Vaccine
- Lung Cancer
- Melanoma Cancer
- Gastrointestinal Cancer
- Brain Cancer
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Pfizer
- Merck & Co Inc
- Eli Lilly and Company
- BioNTech
- Roche Holding AG
- OSE Immunotherapeutics
- Gritstone Bio
- Moderna
- Avidea Technologies
- Vaccibody AS
- Agenus Inc
- Novogene
- ZIOPHARM Oncology
- ISA Pharmaceuticals
- BrightPath Biotherapeutics
- Vaximm AG
- Medigene AG
- Genocea Biosciences Inc
- Advaxis
- Nouscom
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Neoantigen Vaccine Market Size 2018-2029
2.1.2 Neoantigen Vaccine Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Neoantigen Vaccine Segment by Type
2.2.1 Personalized Vaccine
2.2.2 Off-the shelf Vaccine
2.3 Neoantigen Vaccine Market Size by Type
2.3.1 Neoantigen Vaccine Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Neoantigen Vaccine Market Size Market Share by Type (2018-2023)
2.4 Neoantigen Vaccine Segment by Application
2.4.1 Lung Cancer
2.4.2 Melanoma Cancer
2.4.3 Gastrointestinal Cancer
2.4.4 Brain Cancer
2.4.5 Others
2.5 Neoantigen Vaccine Market Size by Application
2.5.1 Neoantigen Vaccine Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Neoantigen Vaccine Market Size Market Share by Application (2018-2023)
3 NEOANTIGEN VACCINE MARKET SIZE BY PLAYER
3.1 Neoantigen Vaccine Market Size Market Share by Players
3.1.1 Global Neoantigen Vaccine Revenue by Players (2018-2023)
3.1.2 Global Neoantigen Vaccine Revenue Market Share by Players (2018-2023)
3.2 Global Neoantigen Vaccine Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 NEOANTIGEN VACCINE BY REGIONS
4.1 Neoantigen Vaccine Market Size by Regions (2018-2023)
4.2 Americas Neoantigen Vaccine Market Size Growth (2018-2023)
4.3 APAC Neoantigen Vaccine Market Size Growth (2018-2023)
4.4 Europe Neoantigen Vaccine Market Size Growth (2018-2023)
4.5 Middle East & Africa Neoantigen Vaccine Market Size Growth (2018-2023)
5 AMERICAS
5.1 Americas Neoantigen Vaccine Market Size by Country (2018-2023)
5.2 Americas Neoantigen Vaccine Market Size by Type (2018-2023)
5.3 Americas Neoantigen Vaccine Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neoantigen Vaccine Market Size by Region (2018-2023)
6.2 APAC Neoantigen Vaccine Market Size by Type (2018-2023)
6.3 APAC Neoantigen Vaccine Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Neoantigen Vaccine by Country (2018-2023)
7.2 Europe Neoantigen Vaccine Market Size by Type (2018-2023)
7.3 Europe Neoantigen Vaccine Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Neoantigen Vaccine by Region (2018-2023)
8.2 Middle East & Africa Neoantigen Vaccine Market Size by Type (2018-2023)
8.3 Middle East & Africa Neoantigen Vaccine Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL NEOANTIGEN VACCINE MARKET FORECAST
10.1 Global Neoantigen Vaccine Forecast by Regions (2024-2029)
10.1.1 Global Neoantigen Vaccine Forecast by Regions (2024-2029)
10.1.2 Americas Neoantigen Vaccine Forecast
10.1.3 APAC Neoantigen Vaccine Forecast
10.1.4 Europe Neoantigen Vaccine Forecast
10.1.5 Middle East & Africa Neoantigen Vaccine Forecast
10.2 Americas Neoantigen Vaccine Forecast by Country (2024-2029)
10.2.1 United States Neoantigen Vaccine Market Forecast
10.2.2 Canada Neoantigen Vaccine Market Forecast
10.2.3 Mexico Neoantigen Vaccine Market Forecast
10.2.4 Brazil Neoantigen Vaccine Market Forecast
10.3 APAC Neoantigen Vaccine Forecast by Region (2024-2029)
10.3.1 China Neoantigen Vaccine Market Forecast
10.3.2 Japan Neoantigen Vaccine Market Forecast
10.3.3 Korea Neoantigen Vaccine Market Forecast
10.3.4 Southeast Asia Neoantigen Vaccine Market Forecast
10.3.5 India Neoantigen Vaccine Market Forecast
10.3.6 Australia Neoantigen Vaccine Market Forecast
10.4 Europe Neoantigen Vaccine Forecast by Country (2024-2029)
10.4.1 Germany Neoantigen Vaccine Market Forecast
10.4.2 France Neoantigen Vaccine Market Forecast
10.4.3 UK Neoantigen Vaccine Market Forecast
10.4.4 Italy Neoantigen Vaccine Market Forecast
10.4.5 Russia Neoantigen Vaccine Market Forecast
10.5 Middle East & Africa Neoantigen Vaccine Forecast by Region (2024-2029)
10.5.1 Egypt Neoantigen Vaccine Market Forecast
10.5.2 South Africa Neoantigen Vaccine Market Forecast
10.5.3 Israel Neoantigen Vaccine Market Forecast
10.5.4 Turkey Neoantigen Vaccine Market Forecast
10.5.5 GCC Countries Neoantigen Vaccine Market Forecast
10.6 Global Neoantigen Vaccine Forecast by Type (2024-2029)
10.7 Global Neoantigen Vaccine Forecast by Application (2024-2029)
11 KEY PLAYERS ANALYSIS
11.1 Pfizer
11.1.1 Pfizer Company Information
11.1.2 Pfizer Neoantigen Vaccine Product Offered
11.1.3 Pfizer Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Pfizer Main Business Overview
11.1.5 Pfizer Latest Developments
11.2 Merck & Co Inc
11.2.1 Merck & Co Inc Company Information
11.2.2 Merck & Co Inc Neoantigen Vaccine Product Offered
11.2.3 Merck & Co Inc Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Merck & Co Inc Main Business Overview
11.2.5 Merck & Co Inc Latest Developments
11.3 Eli Lilly and Company
11.3.1 Eli Lilly and Company Company Information
11.3.2 Eli Lilly and Company Neoantigen Vaccine Product Offered
11.3.3 Eli Lilly and Company Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Eli Lilly and Company Main Business Overview
11.3.5 Eli Lilly and Company Latest Developments
11.4 BioNTech
11.4.1 BioNTech Company Information
11.4.2 BioNTech Neoantigen Vaccine Product Offered
11.4.3 BioNTech Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 BioNTech Main Business Overview
11.4.5 BioNTech Latest Developments
11.5 Roche Holding AG
11.5.1 Roche Holding AG Company Information
11.5.2 Roche Holding AG Neoantigen Vaccine Product Offered
11.5.3 Roche Holding AG Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Roche Holding AG Main Business Overview
11.5.5 Roche Holding AG Latest Developments
11.6 OSE Immunotherapeutics
11.6.1 OSE Immunotherapeutics Company Information
11.6.2 OSE Immunotherapeutics Neoantigen Vaccine Product Offered
11.6.3 OSE Immunotherapeutics Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 OSE Immunotherapeutics Main Business Overview
11.6.5 OSE Immunotherapeutics Latest Developments
11.7 Gritstone Bio
11.7.1 Gritstone Bio Company Information
11.7.2 Gritstone Bio Neoantigen Vaccine Product Offered
11.7.3 Gritstone Bio Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Gritstone Bio Main Business Overview
11.7.5 Gritstone Bio Latest Developments
11.8 Moderna
11.8.1 Moderna Company Information
11.8.2 Moderna Neoantigen Vaccine Product Offered
11.8.3 Moderna Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Moderna Main Business Overview
11.8.5 Moderna Latest Developments
11.9 Avidea Technologies
11.9.1 Avidea Technologies Company Information
11.9.2 Avidea Technologies Neoantigen Vaccine Product Offered
11.9.3 Avidea Technologies Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Avidea Technologies Main Business Overview
11.9.5 Avidea Technologies Latest Developments
11.10 Vaccibody AS
11.10.1 Vaccibody AS Company Information
11.10.2 Vaccibody AS Neoantigen Vaccine Product Offered
11.10.3 Vaccibody AS Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Vaccibody AS Main Business Overview
11.10.5 Vaccibody AS Latest Developments
11.11 Agenus Inc
11.11.1 Agenus Inc Company Information
11.11.2 Agenus Inc Neoantigen Vaccine Product Offered
11.11.3 Agenus Inc Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Agenus Inc Main Business Overview
11.11.5 Agenus Inc Latest Developments
11.12 Novogene
11.12.1 Novogene Company Information
11.12.2 Novogene Neoantigen Vaccine Product Offered
11.12.3 Novogene Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Novogene Main Business Overview
11.12.5 Novogene Latest Developments
11.13 ZIOPHARM Oncology
11.13.1 ZIOPHARM Oncology Company Information
11.13.2 ZIOPHARM Oncology Neoantigen Vaccine Product Offered
11.13.3 ZIOPHARM Oncology Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 ZIOPHARM Oncology Main Business Overview
11.13.5 ZIOPHARM Oncology Latest Developments
11.14 ISA Pharmaceuticals
11.14.1 ISA Pharmaceuticals Company Information
11.14.2 ISA Pharmaceuticals Neoantigen Vaccine Product Offered
11.14.3 ISA Pharmaceuticals Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 ISA Pharmaceuticals Main Business Overview
11.14.5 ISA Pharmaceuticals Latest Developments
11.15 BrightPath Biotherapeutics
11.15.1 BrightPath Biotherapeutics Company Information
11.15.2 BrightPath Biotherapeutics Neoantigen Vaccine Product Offered
11.15.3 BrightPath Biotherapeutics Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 BrightPath Biotherapeutics Main Business Overview
11.15.5 BrightPath Biotherapeutics Latest Developments
11.16 Vaximm AG
11.16.1 Vaximm AG Company Information
11.16.2 Vaximm AG Neoantigen Vaccine Product Offered
11.16.3 Vaximm AG Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.16.4 Vaximm AG Main Business Overview
11.16.5 Vaximm AG Latest Developments
11.17 Medigene AG
11.17.1 Medigene AG Company Information
11.17.2 Medigene AG Neoantigen Vaccine Product Offered
11.17.3 Medigene AG Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.17.4 Medigene AG Main Business Overview
11.17.5 Medigene AG Latest Developments
11.18 Genocea Biosciences Inc
11.18.1 Genocea Biosciences Inc Company Information
11.18.2 Genocea Biosciences Inc Neoantigen Vaccine Product Offered
11.18.3 Genocea Biosciences Inc Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.18.4 Genocea Biosciences Inc Main Business Overview
11.18.5 Genocea Biosciences Inc Latest Developments
11.19 Advaxis
11.19.1 Advaxis Company Information
11.19.2 Advaxis Neoantigen Vaccine Product Offered
11.19.3 Advaxis Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.19.4 Advaxis Main Business Overview
11.19.5 Advaxis Latest Developments
11.20 Nouscom
11.20.1 Nouscom Company Information
11.20.2 Nouscom Neoantigen Vaccine Product Offered
11.20.3 Nouscom Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.20.4 Nouscom Main Business Overview
11.20.5 Nouscom Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Neoantigen Vaccine Market Size 2018-2029
2.1.2 Neoantigen Vaccine Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Neoantigen Vaccine Segment by Type
2.2.1 Personalized Vaccine
2.2.2 Off-the shelf Vaccine
2.3 Neoantigen Vaccine Market Size by Type
2.3.1 Neoantigen Vaccine Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Neoantigen Vaccine Market Size Market Share by Type (2018-2023)
2.4 Neoantigen Vaccine Segment by Application
2.4.1 Lung Cancer
2.4.2 Melanoma Cancer
2.4.3 Gastrointestinal Cancer
2.4.4 Brain Cancer
2.4.5 Others
2.5 Neoantigen Vaccine Market Size by Application
2.5.1 Neoantigen Vaccine Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Neoantigen Vaccine Market Size Market Share by Application (2018-2023)
3 NEOANTIGEN VACCINE MARKET SIZE BY PLAYER
3.1 Neoantigen Vaccine Market Size Market Share by Players
3.1.1 Global Neoantigen Vaccine Revenue by Players (2018-2023)
3.1.2 Global Neoantigen Vaccine Revenue Market Share by Players (2018-2023)
3.2 Global Neoantigen Vaccine Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 NEOANTIGEN VACCINE BY REGIONS
4.1 Neoantigen Vaccine Market Size by Regions (2018-2023)
4.2 Americas Neoantigen Vaccine Market Size Growth (2018-2023)
4.3 APAC Neoantigen Vaccine Market Size Growth (2018-2023)
4.4 Europe Neoantigen Vaccine Market Size Growth (2018-2023)
4.5 Middle East & Africa Neoantigen Vaccine Market Size Growth (2018-2023)
5 AMERICAS
5.1 Americas Neoantigen Vaccine Market Size by Country (2018-2023)
5.2 Americas Neoantigen Vaccine Market Size by Type (2018-2023)
5.3 Americas Neoantigen Vaccine Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neoantigen Vaccine Market Size by Region (2018-2023)
6.2 APAC Neoantigen Vaccine Market Size by Type (2018-2023)
6.3 APAC Neoantigen Vaccine Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Neoantigen Vaccine by Country (2018-2023)
7.2 Europe Neoantigen Vaccine Market Size by Type (2018-2023)
7.3 Europe Neoantigen Vaccine Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Neoantigen Vaccine by Region (2018-2023)
8.2 Middle East & Africa Neoantigen Vaccine Market Size by Type (2018-2023)
8.3 Middle East & Africa Neoantigen Vaccine Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL NEOANTIGEN VACCINE MARKET FORECAST
10.1 Global Neoantigen Vaccine Forecast by Regions (2024-2029)
10.1.1 Global Neoantigen Vaccine Forecast by Regions (2024-2029)
10.1.2 Americas Neoantigen Vaccine Forecast
10.1.3 APAC Neoantigen Vaccine Forecast
10.1.4 Europe Neoantigen Vaccine Forecast
10.1.5 Middle East & Africa Neoantigen Vaccine Forecast
10.2 Americas Neoantigen Vaccine Forecast by Country (2024-2029)
10.2.1 United States Neoantigen Vaccine Market Forecast
10.2.2 Canada Neoantigen Vaccine Market Forecast
10.2.3 Mexico Neoantigen Vaccine Market Forecast
10.2.4 Brazil Neoantigen Vaccine Market Forecast
10.3 APAC Neoantigen Vaccine Forecast by Region (2024-2029)
10.3.1 China Neoantigen Vaccine Market Forecast
10.3.2 Japan Neoantigen Vaccine Market Forecast
10.3.3 Korea Neoantigen Vaccine Market Forecast
10.3.4 Southeast Asia Neoantigen Vaccine Market Forecast
10.3.5 India Neoantigen Vaccine Market Forecast
10.3.6 Australia Neoantigen Vaccine Market Forecast
10.4 Europe Neoantigen Vaccine Forecast by Country (2024-2029)
10.4.1 Germany Neoantigen Vaccine Market Forecast
10.4.2 France Neoantigen Vaccine Market Forecast
10.4.3 UK Neoantigen Vaccine Market Forecast
10.4.4 Italy Neoantigen Vaccine Market Forecast
10.4.5 Russia Neoantigen Vaccine Market Forecast
10.5 Middle East & Africa Neoantigen Vaccine Forecast by Region (2024-2029)
10.5.1 Egypt Neoantigen Vaccine Market Forecast
10.5.2 South Africa Neoantigen Vaccine Market Forecast
10.5.3 Israel Neoantigen Vaccine Market Forecast
10.5.4 Turkey Neoantigen Vaccine Market Forecast
10.5.5 GCC Countries Neoantigen Vaccine Market Forecast
10.6 Global Neoantigen Vaccine Forecast by Type (2024-2029)
10.7 Global Neoantigen Vaccine Forecast by Application (2024-2029)
11 KEY PLAYERS ANALYSIS
11.1 Pfizer
11.1.1 Pfizer Company Information
11.1.2 Pfizer Neoantigen Vaccine Product Offered
11.1.3 Pfizer Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Pfizer Main Business Overview
11.1.5 Pfizer Latest Developments
11.2 Merck & Co Inc
11.2.1 Merck & Co Inc Company Information
11.2.2 Merck & Co Inc Neoantigen Vaccine Product Offered
11.2.3 Merck & Co Inc Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Merck & Co Inc Main Business Overview
11.2.5 Merck & Co Inc Latest Developments
11.3 Eli Lilly and Company
11.3.1 Eli Lilly and Company Company Information
11.3.2 Eli Lilly and Company Neoantigen Vaccine Product Offered
11.3.3 Eli Lilly and Company Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Eli Lilly and Company Main Business Overview
11.3.5 Eli Lilly and Company Latest Developments
11.4 BioNTech
11.4.1 BioNTech Company Information
11.4.2 BioNTech Neoantigen Vaccine Product Offered
11.4.3 BioNTech Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 BioNTech Main Business Overview
11.4.5 BioNTech Latest Developments
11.5 Roche Holding AG
11.5.1 Roche Holding AG Company Information
11.5.2 Roche Holding AG Neoantigen Vaccine Product Offered
11.5.3 Roche Holding AG Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Roche Holding AG Main Business Overview
11.5.5 Roche Holding AG Latest Developments
11.6 OSE Immunotherapeutics
11.6.1 OSE Immunotherapeutics Company Information
11.6.2 OSE Immunotherapeutics Neoantigen Vaccine Product Offered
11.6.3 OSE Immunotherapeutics Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 OSE Immunotherapeutics Main Business Overview
11.6.5 OSE Immunotherapeutics Latest Developments
11.7 Gritstone Bio
11.7.1 Gritstone Bio Company Information
11.7.2 Gritstone Bio Neoantigen Vaccine Product Offered
11.7.3 Gritstone Bio Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Gritstone Bio Main Business Overview
11.7.5 Gritstone Bio Latest Developments
11.8 Moderna
11.8.1 Moderna Company Information
11.8.2 Moderna Neoantigen Vaccine Product Offered
11.8.3 Moderna Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Moderna Main Business Overview
11.8.5 Moderna Latest Developments
11.9 Avidea Technologies
11.9.1 Avidea Technologies Company Information
11.9.2 Avidea Technologies Neoantigen Vaccine Product Offered
11.9.3 Avidea Technologies Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Avidea Technologies Main Business Overview
11.9.5 Avidea Technologies Latest Developments
11.10 Vaccibody AS
11.10.1 Vaccibody AS Company Information
11.10.2 Vaccibody AS Neoantigen Vaccine Product Offered
11.10.3 Vaccibody AS Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Vaccibody AS Main Business Overview
11.10.5 Vaccibody AS Latest Developments
11.11 Agenus Inc
11.11.1 Agenus Inc Company Information
11.11.2 Agenus Inc Neoantigen Vaccine Product Offered
11.11.3 Agenus Inc Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Agenus Inc Main Business Overview
11.11.5 Agenus Inc Latest Developments
11.12 Novogene
11.12.1 Novogene Company Information
11.12.2 Novogene Neoantigen Vaccine Product Offered
11.12.3 Novogene Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Novogene Main Business Overview
11.12.5 Novogene Latest Developments
11.13 ZIOPHARM Oncology
11.13.1 ZIOPHARM Oncology Company Information
11.13.2 ZIOPHARM Oncology Neoantigen Vaccine Product Offered
11.13.3 ZIOPHARM Oncology Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 ZIOPHARM Oncology Main Business Overview
11.13.5 ZIOPHARM Oncology Latest Developments
11.14 ISA Pharmaceuticals
11.14.1 ISA Pharmaceuticals Company Information
11.14.2 ISA Pharmaceuticals Neoantigen Vaccine Product Offered
11.14.3 ISA Pharmaceuticals Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 ISA Pharmaceuticals Main Business Overview
11.14.5 ISA Pharmaceuticals Latest Developments
11.15 BrightPath Biotherapeutics
11.15.1 BrightPath Biotherapeutics Company Information
11.15.2 BrightPath Biotherapeutics Neoantigen Vaccine Product Offered
11.15.3 BrightPath Biotherapeutics Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 BrightPath Biotherapeutics Main Business Overview
11.15.5 BrightPath Biotherapeutics Latest Developments
11.16 Vaximm AG
11.16.1 Vaximm AG Company Information
11.16.2 Vaximm AG Neoantigen Vaccine Product Offered
11.16.3 Vaximm AG Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.16.4 Vaximm AG Main Business Overview
11.16.5 Vaximm AG Latest Developments
11.17 Medigene AG
11.17.1 Medigene AG Company Information
11.17.2 Medigene AG Neoantigen Vaccine Product Offered
11.17.3 Medigene AG Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.17.4 Medigene AG Main Business Overview
11.17.5 Medigene AG Latest Developments
11.18 Genocea Biosciences Inc
11.18.1 Genocea Biosciences Inc Company Information
11.18.2 Genocea Biosciences Inc Neoantigen Vaccine Product Offered
11.18.3 Genocea Biosciences Inc Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.18.4 Genocea Biosciences Inc Main Business Overview
11.18.5 Genocea Biosciences Inc Latest Developments
11.19 Advaxis
11.19.1 Advaxis Company Information
11.19.2 Advaxis Neoantigen Vaccine Product Offered
11.19.3 Advaxis Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.19.4 Advaxis Main Business Overview
11.19.5 Advaxis Latest Developments
11.20 Nouscom
11.20.1 Nouscom Company Information
11.20.2 Nouscom Neoantigen Vaccine Product Offered
11.20.3 Nouscom Neoantigen Vaccine Revenue, Gross Margin and Market Share (2018-2023)
11.20.4 Nouscom Main Business Overview
11.20.5 Nouscom Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Neoantigen Vaccine Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Personalized Vaccine
Table 3. Major Players of Off-the shelf Vaccine
Table 4. Neoantigen Vaccine Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 5. Global Neoantigen Vaccine Market Size by Type (2018-2023) & ($ Millions)
Table 6. Global Neoantigen Vaccine Market Size Market Share by Type (2018-2023)
Table 7. Neoantigen Vaccine Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 8. Global Neoantigen Vaccine Market Size by Application (2018-2023) & ($ Millions)
Table 9. Global Neoantigen Vaccine Market Size Market Share by Application (2018-2023)
Table 10. Global Neoantigen Vaccine Revenue by Players (2018-2023) & ($ Millions)
Table 11. Global Neoantigen Vaccine Revenue Market Share by Player (2018-2023)
Table 12. Neoantigen Vaccine Key Players Head office and Products Offered
Table 13. Neoantigen Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global Neoantigen Vaccine Market Size by Regions 2018-2023 & ($ Millions)
Table 17. Global Neoantigen Vaccine Market Size Market Share by Regions (2018-2023)
Table 18. Global Neoantigen Vaccine Revenue by Country/Region (2018-2023) & ($ millions)
Table 19. Global Neoantigen Vaccine Revenue Market Share by Country/Region (2018-2023)
Table 20. Americas Neoantigen Vaccine Market Size by Country (2018-2023) & ($ Millions)
Table 21. Americas Neoantigen Vaccine Market Size Market Share by Country (2018-2023)
Table 22. Americas Neoantigen Vaccine Market Size by Type (2018-2023) & ($ Millions)
Table 23. Americas Neoantigen Vaccine Market Size Market Share by Type (2018-2023)
Table 24. Americas Neoantigen Vaccine Market Size by Application (2018-2023) & ($ Millions)
Table 25. Americas Neoantigen Vaccine Market Size Market Share by Application (2018-2023)
Table 26. APAC Neoantigen Vaccine Market Size by Region (2018-2023) & ($ Millions)
Table 27. APAC Neoantigen Vaccine Market Size Market Share by Region (2018-2023)
Table 28. APAC Neoantigen Vaccine Market Size by Type (2018-2023) & ($ Millions)
Table 29. APAC Neoantigen Vaccine Market Size Market Share by Type (2018-2023)
Table 30. APAC Neoantigen Vaccine Market Size by Application (2018-2023) & ($ Millions)
Table 31. APAC Neoantigen Vaccine Market Size Market Share by Application (2018-2023)
Table 32. Europe Neoantigen Vaccine Market Size by Country (2018-2023) & ($ Millions)
Table 33. Europe Neoantigen Vaccine Market Size Market Share by Country (2018-2023)
Table 34. Europe Neoantigen Vaccine Market Size by Type (2018-2023) & ($ Millions)
Table 35. Europe Neoantigen Vaccine Market Size Market Share by Type (2018-2023)
Table 36. Europe Neoantigen Vaccine Market Size by Application (2018-2023) & ($ Millions)
Table 37. Europe Neoantigen Vaccine Market Size Market Share by Application (2018-2023)
Table 38. Middle East & Africa Neoantigen Vaccine Market Size by Region (2018-2023) & ($ Millions)
Table 39. Middle East & Africa Neoantigen Vaccine Market Size Market Share by Region (2018-2023)
Table 40. Middle East & Africa Neoantigen Vaccine Market Size by Type (2018-2023) & ($ Millions)
Table 41. Middle East & Africa Neoantigen Vaccine Market Size Market Share by Type (2018-2023)
Table 42. Middle East & Africa Neoantigen Vaccine Market Size by Application (2018-2023) & ($ Millions)
Table 43. Middle East & Africa Neoantigen Vaccine Market Size Market Share by Application (2018-2023)
Table 44. Key Market Drivers & Growth Opportunities of Neoantigen Vaccine
Table 45. Key Market Challenges & Risks of Neoantigen Vaccine
Table 46. Key Industry Trends of Neoantigen Vaccine
Table 47. Global Neoantigen Vaccine Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 48. Global Neoantigen Vaccine Market Size Market Share Forecast by Regions (2024-2029)
Table 49. Global Neoantigen Vaccine Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 50. Global Neoantigen Vaccine Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 51. Pfizer Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 52. Pfizer Neoantigen Vaccine Product Offered
Table 53. Pfizer Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 54. Pfizer Main Business
Table 55. Pfizer Latest Developments
Table 56. Merck & Co Inc Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 57. Merck & Co Inc Neoantigen Vaccine Product Offered
Table 58. Merck & Co Inc Main Business
Table 59. Merck & Co Inc Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 60. Merck & Co Inc Latest Developments
Table 61. Eli Lilly and Company Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 62. Eli Lilly and Company Neoantigen Vaccine Product Offered
Table 63. Eli Lilly and Company Main Business
Table 64. Eli Lilly and Company Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 65. Eli Lilly and Company Latest Developments
Table 66. BioNTech Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 67. BioNTech Neoantigen Vaccine Product Offered
Table 68. BioNTech Main Business
Table 69. BioNTech Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 70. BioNTech Latest Developments
Table 71. Roche Holding AG Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 72. Roche Holding AG Neoantigen Vaccine Product Offered
Table 73. Roche Holding AG Main Business
Table 74. Roche Holding AG Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 75. Roche Holding AG Latest Developments
Table 76. OSE Immunotherapeutics Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 77. OSE Immunotherapeutics Neoantigen Vaccine Product Offered
Table 78. OSE Immunotherapeutics Main Business
Table 79. OSE Immunotherapeutics Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 80. OSE Immunotherapeutics Latest Developments
Table 81. Gritstone Bio Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 82. Gritstone Bio Neoantigen Vaccine Product Offered
Table 83. Gritstone Bio Main Business
Table 84. Gritstone Bio Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 85. Gritstone Bio Latest Developments
Table 86. Moderna Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 87. Moderna Neoantigen Vaccine Product Offered
Table 88. Moderna Main Business
Table 89. Moderna Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 90. Moderna Latest Developments
Table 91. Avidea Technologies Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 92. Avidea Technologies Neoantigen Vaccine Product Offered
Table 93. Avidea Technologies Main Business
Table 94. Avidea Technologies Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 95. Avidea Technologies Latest Developments
Table 96. Vaccibody AS Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 97. Vaccibody AS Neoantigen Vaccine Product Offered
Table 98. Vaccibody AS Main Business
Table 99. Vaccibody AS Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 100. Vaccibody AS Latest Developments
Table 101. Agenus Inc Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 102. Agenus Inc Neoantigen Vaccine Product Offered
Table 103. Agenus Inc Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 104. Agenus Inc Main Business
Table 105. Agenus Inc Latest Developments
Table 106. Novogene Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 107. Novogene Neoantigen Vaccine Product Offered
Table 108. Novogene Main Business
Table 109. Novogene Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 110. Novogene Latest Developments
Table 111. ZIOPHARM Oncology Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 112. ZIOPHARM Oncology Neoantigen Vaccine Product Offered
Table 113. ZIOPHARM Oncology Main Business
Table 114. ZIOPHARM Oncology Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 115. ZIOPHARM Oncology Latest Developments
Table 116. ISA Pharmaceuticals Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 117. ISA Pharmaceuticals Neoantigen Vaccine Product Offered
Table 118. ISA Pharmaceuticals Main Business
Table 119. ISA Pharmaceuticals Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 120. ISA Pharmaceuticals Latest Developments
Table 121. BrightPath Biotherapeutics Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 122. BrightPath Biotherapeutics Neoantigen Vaccine Product Offered
Table 123. BrightPath Biotherapeutics Main Business
Table 124. BrightPath Biotherapeutics Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 125. BrightPath Biotherapeutics Latest Developments
Table 126. Vaximm AG Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 127. Vaximm AG Neoantigen Vaccine Product Offered
Table 128. Vaximm AG Main Business
Table 129. Vaximm AG Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 130. Vaximm AG Latest Developments
Table 131. Medigene AG Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 132. Medigene AG Neoantigen Vaccine Product Offered
Table 133. Medigene AG Main Business
Table 134. Medigene AG Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 135. Medigene AG Latest Developments
Table 136. Genocea Biosciences Inc Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 137. Genocea Biosciences Inc Neoantigen Vaccine Product Offered
Table 138. Genocea Biosciences Inc Main Business
Table 139. Genocea Biosciences Inc Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 140. Genocea Biosciences Inc Latest Developments
Table 141. Advaxis Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 142. Advaxis Neoantigen Vaccine Product Offered
Table 143. Advaxis Main Business
Table 144. Advaxis Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 145. Advaxis Latest Developments
Table 146. Nouscom Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 147. Nouscom Neoantigen Vaccine Product Offered
Table 148. Nouscom Main Business
Table 149. Nouscom Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 150. Nouscom Latest Developments
Table 1. Neoantigen Vaccine Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Personalized Vaccine
Table 3. Major Players of Off-the shelf Vaccine
Table 4. Neoantigen Vaccine Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 5. Global Neoantigen Vaccine Market Size by Type (2018-2023) & ($ Millions)
Table 6. Global Neoantigen Vaccine Market Size Market Share by Type (2018-2023)
Table 7. Neoantigen Vaccine Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 8. Global Neoantigen Vaccine Market Size by Application (2018-2023) & ($ Millions)
Table 9. Global Neoantigen Vaccine Market Size Market Share by Application (2018-2023)
Table 10. Global Neoantigen Vaccine Revenue by Players (2018-2023) & ($ Millions)
Table 11. Global Neoantigen Vaccine Revenue Market Share by Player (2018-2023)
Table 12. Neoantigen Vaccine Key Players Head office and Products Offered
Table 13. Neoantigen Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global Neoantigen Vaccine Market Size by Regions 2018-2023 & ($ Millions)
Table 17. Global Neoantigen Vaccine Market Size Market Share by Regions (2018-2023)
Table 18. Global Neoantigen Vaccine Revenue by Country/Region (2018-2023) & ($ millions)
Table 19. Global Neoantigen Vaccine Revenue Market Share by Country/Region (2018-2023)
Table 20. Americas Neoantigen Vaccine Market Size by Country (2018-2023) & ($ Millions)
Table 21. Americas Neoantigen Vaccine Market Size Market Share by Country (2018-2023)
Table 22. Americas Neoantigen Vaccine Market Size by Type (2018-2023) & ($ Millions)
Table 23. Americas Neoantigen Vaccine Market Size Market Share by Type (2018-2023)
Table 24. Americas Neoantigen Vaccine Market Size by Application (2018-2023) & ($ Millions)
Table 25. Americas Neoantigen Vaccine Market Size Market Share by Application (2018-2023)
Table 26. APAC Neoantigen Vaccine Market Size by Region (2018-2023) & ($ Millions)
Table 27. APAC Neoantigen Vaccine Market Size Market Share by Region (2018-2023)
Table 28. APAC Neoantigen Vaccine Market Size by Type (2018-2023) & ($ Millions)
Table 29. APAC Neoantigen Vaccine Market Size Market Share by Type (2018-2023)
Table 30. APAC Neoantigen Vaccine Market Size by Application (2018-2023) & ($ Millions)
Table 31. APAC Neoantigen Vaccine Market Size Market Share by Application (2018-2023)
Table 32. Europe Neoantigen Vaccine Market Size by Country (2018-2023) & ($ Millions)
Table 33. Europe Neoantigen Vaccine Market Size Market Share by Country (2018-2023)
Table 34. Europe Neoantigen Vaccine Market Size by Type (2018-2023) & ($ Millions)
Table 35. Europe Neoantigen Vaccine Market Size Market Share by Type (2018-2023)
Table 36. Europe Neoantigen Vaccine Market Size by Application (2018-2023) & ($ Millions)
Table 37. Europe Neoantigen Vaccine Market Size Market Share by Application (2018-2023)
Table 38. Middle East & Africa Neoantigen Vaccine Market Size by Region (2018-2023) & ($ Millions)
Table 39. Middle East & Africa Neoantigen Vaccine Market Size Market Share by Region (2018-2023)
Table 40. Middle East & Africa Neoantigen Vaccine Market Size by Type (2018-2023) & ($ Millions)
Table 41. Middle East & Africa Neoantigen Vaccine Market Size Market Share by Type (2018-2023)
Table 42. Middle East & Africa Neoantigen Vaccine Market Size by Application (2018-2023) & ($ Millions)
Table 43. Middle East & Africa Neoantigen Vaccine Market Size Market Share by Application (2018-2023)
Table 44. Key Market Drivers & Growth Opportunities of Neoantigen Vaccine
Table 45. Key Market Challenges & Risks of Neoantigen Vaccine
Table 46. Key Industry Trends of Neoantigen Vaccine
Table 47. Global Neoantigen Vaccine Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 48. Global Neoantigen Vaccine Market Size Market Share Forecast by Regions (2024-2029)
Table 49. Global Neoantigen Vaccine Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 50. Global Neoantigen Vaccine Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 51. Pfizer Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 52. Pfizer Neoantigen Vaccine Product Offered
Table 53. Pfizer Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 54. Pfizer Main Business
Table 55. Pfizer Latest Developments
Table 56. Merck & Co Inc Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 57. Merck & Co Inc Neoantigen Vaccine Product Offered
Table 58. Merck & Co Inc Main Business
Table 59. Merck & Co Inc Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 60. Merck & Co Inc Latest Developments
Table 61. Eli Lilly and Company Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 62. Eli Lilly and Company Neoantigen Vaccine Product Offered
Table 63. Eli Lilly and Company Main Business
Table 64. Eli Lilly and Company Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 65. Eli Lilly and Company Latest Developments
Table 66. BioNTech Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 67. BioNTech Neoantigen Vaccine Product Offered
Table 68. BioNTech Main Business
Table 69. BioNTech Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 70. BioNTech Latest Developments
Table 71. Roche Holding AG Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 72. Roche Holding AG Neoantigen Vaccine Product Offered
Table 73. Roche Holding AG Main Business
Table 74. Roche Holding AG Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 75. Roche Holding AG Latest Developments
Table 76. OSE Immunotherapeutics Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 77. OSE Immunotherapeutics Neoantigen Vaccine Product Offered
Table 78. OSE Immunotherapeutics Main Business
Table 79. OSE Immunotherapeutics Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 80. OSE Immunotherapeutics Latest Developments
Table 81. Gritstone Bio Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 82. Gritstone Bio Neoantigen Vaccine Product Offered
Table 83. Gritstone Bio Main Business
Table 84. Gritstone Bio Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 85. Gritstone Bio Latest Developments
Table 86. Moderna Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 87. Moderna Neoantigen Vaccine Product Offered
Table 88. Moderna Main Business
Table 89. Moderna Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 90. Moderna Latest Developments
Table 91. Avidea Technologies Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 92. Avidea Technologies Neoantigen Vaccine Product Offered
Table 93. Avidea Technologies Main Business
Table 94. Avidea Technologies Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 95. Avidea Technologies Latest Developments
Table 96. Vaccibody AS Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 97. Vaccibody AS Neoantigen Vaccine Product Offered
Table 98. Vaccibody AS Main Business
Table 99. Vaccibody AS Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 100. Vaccibody AS Latest Developments
Table 101. Agenus Inc Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 102. Agenus Inc Neoantigen Vaccine Product Offered
Table 103. Agenus Inc Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 104. Agenus Inc Main Business
Table 105. Agenus Inc Latest Developments
Table 106. Novogene Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 107. Novogene Neoantigen Vaccine Product Offered
Table 108. Novogene Main Business
Table 109. Novogene Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 110. Novogene Latest Developments
Table 111. ZIOPHARM Oncology Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 112. ZIOPHARM Oncology Neoantigen Vaccine Product Offered
Table 113. ZIOPHARM Oncology Main Business
Table 114. ZIOPHARM Oncology Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 115. ZIOPHARM Oncology Latest Developments
Table 116. ISA Pharmaceuticals Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 117. ISA Pharmaceuticals Neoantigen Vaccine Product Offered
Table 118. ISA Pharmaceuticals Main Business
Table 119. ISA Pharmaceuticals Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 120. ISA Pharmaceuticals Latest Developments
Table 121. BrightPath Biotherapeutics Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 122. BrightPath Biotherapeutics Neoantigen Vaccine Product Offered
Table 123. BrightPath Biotherapeutics Main Business
Table 124. BrightPath Biotherapeutics Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 125. BrightPath Biotherapeutics Latest Developments
Table 126. Vaximm AG Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 127. Vaximm AG Neoantigen Vaccine Product Offered
Table 128. Vaximm AG Main Business
Table 129. Vaximm AG Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 130. Vaximm AG Latest Developments
Table 131. Medigene AG Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 132. Medigene AG Neoantigen Vaccine Product Offered
Table 133. Medigene AG Main Business
Table 134. Medigene AG Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 135. Medigene AG Latest Developments
Table 136. Genocea Biosciences Inc Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 137. Genocea Biosciences Inc Neoantigen Vaccine Product Offered
Table 138. Genocea Biosciences Inc Main Business
Table 139. Genocea Biosciences Inc Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 140. Genocea Biosciences Inc Latest Developments
Table 141. Advaxis Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 142. Advaxis Neoantigen Vaccine Product Offered
Table 143. Advaxis Main Business
Table 144. Advaxis Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 145. Advaxis Latest Developments
Table 146. Nouscom Details, Company Type, Neoantigen Vaccine Area Served and Its Competitors
Table 147. Nouscom Neoantigen Vaccine Product Offered
Table 148. Nouscom Main Business
Table 149. Nouscom Neoantigen Vaccine Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 150. Nouscom Latest Developments
LIST OF FIGURES
Figure 1. Neoantigen Vaccine Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Neoantigen Vaccine Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. Neoantigen Vaccine Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. Neoantigen Vaccine Sales Market Share by Country/Region (2022)
Figure 8. Neoantigen Vaccine Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global Neoantigen Vaccine Market Size Market Share by Type in 2022
Figure 10. Neoantigen Vaccine in Lung Cancer
Figure 11. Global Neoantigen Vaccine Market: Lung Cancer (2018-2023) & ($ Millions)
Figure 12. Neoantigen Vaccine in Melanoma Cancer
Figure 13. Global Neoantigen Vaccine Market: Melanoma Cancer (2018-2023) & ($ Millions)
Figure 14. Neoantigen Vaccine in Gastrointestinal Cancer
Figure 15. Global Neoantigen Vaccine Market: Gastrointestinal Cancer (2018-2023) & ($ Millions)
Figure 16. Neoantigen Vaccine in Brain Cancer
Figure 17. Global Neoantigen Vaccine Market: Brain Cancer (2018-2023) & ($ Millions)
Figure 18. Neoantigen Vaccine in Others
Figure 19. Global Neoantigen Vaccine Market: Others (2018-2023) & ($ Millions)
Figure 20. Global Neoantigen Vaccine Market Size Market Share by Application in 2022
Figure 21. Global Neoantigen Vaccine Revenue Market Share by Player in 2022
Figure 22. Global Neoantigen Vaccine Market Size Market Share by Regions (2018-2023)
Figure 23. Americas Neoantigen Vaccine Market Size 2018-2023 ($ Millions)
Figure 24. APAC Neoantigen Vaccine Market Size 2018-2023 ($ Millions)
Figure 25. Europe Neoantigen Vaccine Market Size 2018-2023 ($ Millions)
Figure 26. Middle East & Africa Neoantigen Vaccine Market Size 2018-2023 ($ Millions)
Figure 27. Americas Neoantigen Vaccine Value Market Share by Country in 2022
Figure 28. United States Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 29. Canada Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 30. Mexico Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 31. Brazil Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 32. APAC Neoantigen Vaccine Market Size Market Share by Region in 2022
Figure 33. APAC Neoantigen Vaccine Market Size Market Share by Type in 2022
Figure 34. APAC Neoantigen Vaccine Market Size Market Share by Application in 2022
Figure 35. China Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 36. Japan Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 37. Korea Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 38. Southeast Asia Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 39. India Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 40. Australia Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 41. Europe Neoantigen Vaccine Market Size Market Share by Country in 2022
Figure 42. Europe Neoantigen Vaccine Market Size Market Share by Type (2018-2023)
Figure 43. Europe Neoantigen Vaccine Market Size Market Share by Application (2018-2023)
Figure 44. Germany Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 45. France Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 46. UK Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 47. Italy Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 48. Russia Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 49. Middle East & Africa Neoantigen Vaccine Market Size Market Share by Region (2018-2023)
Figure 50. Middle East & Africa Neoantigen Vaccine Market Size Market Share by Type (2018-2023)
Figure 51. Middle East & Africa Neoantigen Vaccine Market Size Market Share by Application (2018-2023)
Figure 52. Egypt Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 53. South Africa Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 54. Israel Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 55. Turkey Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 56. GCC Country Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 57. Americas Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 58. APAC Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 59. Europe Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 60. Middle East & Africa Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 61. United States Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 62. Canada Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 63. Mexico Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 64. Brazil Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 65. China Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 66. Japan Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 67. Korea Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 68. Southeast Asia Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 69. India Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 70. Australia Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 71. Germany Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 72. France Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 73. UK Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 74. Italy Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 75. Russia Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 76. Spain Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 77. Egypt Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 78. South Africa Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 79. Israel Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 80. Turkey Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 81. GCC Countries Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 82. Global Neoantigen Vaccine Market Size Market Share Forecast by Type (2024-2029)
Figure 83. Global Neoantigen Vaccine Market Size Market Share Forecast by Application (2024-2029)
Figure 1. Neoantigen Vaccine Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Neoantigen Vaccine Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. Neoantigen Vaccine Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. Neoantigen Vaccine Sales Market Share by Country/Region (2022)
Figure 8. Neoantigen Vaccine Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global Neoantigen Vaccine Market Size Market Share by Type in 2022
Figure 10. Neoantigen Vaccine in Lung Cancer
Figure 11. Global Neoantigen Vaccine Market: Lung Cancer (2018-2023) & ($ Millions)
Figure 12. Neoantigen Vaccine in Melanoma Cancer
Figure 13. Global Neoantigen Vaccine Market: Melanoma Cancer (2018-2023) & ($ Millions)
Figure 14. Neoantigen Vaccine in Gastrointestinal Cancer
Figure 15. Global Neoantigen Vaccine Market: Gastrointestinal Cancer (2018-2023) & ($ Millions)
Figure 16. Neoantigen Vaccine in Brain Cancer
Figure 17. Global Neoantigen Vaccine Market: Brain Cancer (2018-2023) & ($ Millions)
Figure 18. Neoantigen Vaccine in Others
Figure 19. Global Neoantigen Vaccine Market: Others (2018-2023) & ($ Millions)
Figure 20. Global Neoantigen Vaccine Market Size Market Share by Application in 2022
Figure 21. Global Neoantigen Vaccine Revenue Market Share by Player in 2022
Figure 22. Global Neoantigen Vaccine Market Size Market Share by Regions (2018-2023)
Figure 23. Americas Neoantigen Vaccine Market Size 2018-2023 ($ Millions)
Figure 24. APAC Neoantigen Vaccine Market Size 2018-2023 ($ Millions)
Figure 25. Europe Neoantigen Vaccine Market Size 2018-2023 ($ Millions)
Figure 26. Middle East & Africa Neoantigen Vaccine Market Size 2018-2023 ($ Millions)
Figure 27. Americas Neoantigen Vaccine Value Market Share by Country in 2022
Figure 28. United States Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 29. Canada Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 30. Mexico Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 31. Brazil Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 32. APAC Neoantigen Vaccine Market Size Market Share by Region in 2022
Figure 33. APAC Neoantigen Vaccine Market Size Market Share by Type in 2022
Figure 34. APAC Neoantigen Vaccine Market Size Market Share by Application in 2022
Figure 35. China Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 36. Japan Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 37. Korea Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 38. Southeast Asia Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 39. India Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 40. Australia Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 41. Europe Neoantigen Vaccine Market Size Market Share by Country in 2022
Figure 42. Europe Neoantigen Vaccine Market Size Market Share by Type (2018-2023)
Figure 43. Europe Neoantigen Vaccine Market Size Market Share by Application (2018-2023)
Figure 44. Germany Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 45. France Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 46. UK Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 47. Italy Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 48. Russia Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 49. Middle East & Africa Neoantigen Vaccine Market Size Market Share by Region (2018-2023)
Figure 50. Middle East & Africa Neoantigen Vaccine Market Size Market Share by Type (2018-2023)
Figure 51. Middle East & Africa Neoantigen Vaccine Market Size Market Share by Application (2018-2023)
Figure 52. Egypt Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 53. South Africa Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 54. Israel Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 55. Turkey Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 56. GCC Country Neoantigen Vaccine Market Size Growth 2018-2023 ($ Millions)
Figure 57. Americas Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 58. APAC Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 59. Europe Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 60. Middle East & Africa Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 61. United States Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 62. Canada Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 63. Mexico Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 64. Brazil Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 65. China Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 66. Japan Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 67. Korea Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 68. Southeast Asia Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 69. India Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 70. Australia Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 71. Germany Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 72. France Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 73. UK Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 74. Italy Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 75. Russia Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 76. Spain Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 77. Egypt Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 78. South Africa Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 79. Israel Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 80. Turkey Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 81. GCC Countries Neoantigen Vaccine Market Size 2024-2029 ($ Millions)
Figure 82. Global Neoantigen Vaccine Market Size Market Share Forecast by Type (2024-2029)
Figure 83. Global Neoantigen Vaccine Market Size Market Share Forecast by Application (2024-2029)
